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Abstract
Background: Gene transfer into the amniotic fluid using recombinant adenovirus vectors was
shown previously to result in high efficiency transfer of transgenes into the lungs and intestines.
Adenovirus mediated in utero gene therapy, however, resulted in expression of the transgene for
less than 30 days. Recombinant adenovirus associated viruses (rAAV) have the advantage of
maintaining the viral genome in daughter cells thus providing for long-term expression of
transgenes.
Methods: Recombinant AAV2 carrying green fluorescent protein (GFP) was introduced into the
amniotic sac of fetal rodents and nonhuman primates. Transgene maintenance and expression was
monitor.
Results: Gene transfer resulted in rapid uptake and long-term gene expression in mice, rats, and
non-human primates. Expression and secretion of the reporter gene, GFP, was readily
demonstrated within 72 hours post-therapy. In long-term studies in rats and nonhuman primates,
maintenance of GFP DNA, protein expression, and reporter gene secretion was documented for
over one year.
Conclusions: Because only multipotential stem cells are present at the time of therapy, these data
demonstrated that in utero gene transfer with AAV2 into stem cells resulted in long-term systemic
expression of active transgene roducts. Thus, in utero gene transfer via the amniotic fluid may be
useful in treatment of gene disorders.
Background
In utero gene transfer is a successful method for transfer-
ring genes to the developing fetus. Providing a therapeutic
gene to the developing fetus allows for the treatment of a
genetic defect before the comorbidities of the disease
occur. Many genetic diseases can be detected in utero, and
the prenatal treatment of these diseases could prove ben-
eficial. The fetus provides a unique environment for gene
transfer because one can influence differentiation and
proliferation of target cells. In addition, the fetal environ-
ment provides the additional benefit of an immature
immune system where vectors are not seen as foreign
[1,2].
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This laboratory has shown that in utero gene transfer via
amniotic fluid is an effective method for introducing
genes into epithelial multipotential stem cells of the lung
and intestines [3–8]. Gene transfer is performed at a ges-
tational age comparable to a 5–15 week human (15–16
days in mice; 16–17 days gestation in rats; 90–110 days in
rhesus). During this critical time of development, undif-
ferentiated epithelial cells, the targets for the vectors, line
the lung and intestine. These cells are the targets for our
vectors. Organ development and growth continues after
the infection and the differentiated daughters of the tar-
geted cells continue to express the transgene. Short-term
adenovirus-mediated in utero gene transfer has now been
successfully demonstrated in three species: the mouse, the
rat, and the rhesus primate.
The use of recombinant adenovirus is limited to studies
examining the role of a specific gene during a very limited
time period. The non-integrating properties of the vector
limit expression to the lifespan of the cell-approximately
10 to 30 days in the intestine and lung, respectively.
Recombinant adeno-associated viruses have the advan-
tage of being maintained for longer periods of time, and
the infection of a multipotential stem cell with this vector
would have a significant advantage over adenoviral-medi-
ated gene transfer for many disease models. Experiments
were performed to determine if rAAV2 would infect the
fetal lung and intestines efficiently.
Uptake and expression of AAV2 reporter genes in fetal 
tissues
Mouse fetuses (20 in two liters) at 15–16 day gestation
were infected with rAAV2CMVgfp via intra-amniotic
injection of 108 pfu/ml of amniotic fluid. Whole embryos
at 72 hours post-therapy were fixed, and frozen sections
were prepared for viewing with the deconvoluting micro-
scope. As shown in Fig. 1, the rAAV2 transgene is rapidly
transferred and expressed in both the lungs (panel A) and
intestines (panel B). All other organs, except for the kid-
ney (see below), were negative for gfp-specific staining.
This laboratory has previously demonstrated that trans-
genes delivered by in utero gene transfer expressed pro-
teins that were secreted regardless of the presence or
absence of a secretory signal [5]. In addition, it was further
demonstrated that the kidney, which cannot be infected
via intra-amniotic in utero gene transfer, filters virus-deliv-
ered transgene products from the circulation. Based on
molecular weight, the gap junction in the glomeruli differ-
entially partitions proteins into either the efferent tubules
or glomeruli. Proteins greater than 80,000 molecular
weight collect in the glomeruli while those less than
80,000 pass through the glomeruli and collect in the effer-
ent tubules. The protein in the efferent tubules appears as
an intracellular signal, while in the glomeruli large aggre-
gates of protein were found [5].
By 72 hours post gene transfer, transgene expression was
sufficiently high for systemic circulation of protein (Fig. 1,
Panel C). Because GFP has a molecular weight below
80,000, it was filtered by the kidneys and collected in the
efferent tubules. Although the efferent tubules are posi-
tive, there is no evidence of GFP protein in the glomeruli
(round clusters of blue-stained nuclei with red-stained
membranes. Thus, both adenovirus and rAAV2 vector-
delivered transgenes produce high levels of proteins that
are released into the systemic circulation and subse-
quently filtered by the kidney.
Persistence of rAAV2 DNA and transgene expression in rats
To evaluate the expression and long-term persistence of
rAAV2 genes and extend the efficacy of in utero rAAV2 to
another species, Sprague-Dawley, the rats were treated in
utero at 16 days' gestation with the rAAV2CMVgfp virus.
Tissues were examined for the presence of gfp-specific pro-
tein by immunohistochemistry and DNA by Southern
blot analysis.
At nine months of age, rat lungs were harvested and fixed
for paraffin sections for immunohistochemistry. As
shown in Fig. 2, GFP was readily detected at 9 months of
age in the airways of all animals tested. Thus, rAAV2 vec-
tors readily infected the lungs of rats, and transgene
expression occurs long-term.
Rats were followed up to one year of age, and DNA was
extracted from both the lungs and intestines. Although the
intestines are a primary target of in utero gene transfer
from the amniotic fluid, no GFP DNA was detected by
Southern blot in these tissues. This indicated that the dilu-
tion of transgene had decreased to levels below detection
and /or that the original transfer efficiency of the intestine
multipotential stem cells was poor. In contrast, GFP DNA
was found in all the rats' lungs at 12 months of age as
demonstrated in Fig. 3.
Non-human primate studies
The in utero uptake of the rAAV2 in the mouse suggests
that this vector could be effective, for the reversal of met-
abolic defects. For this gene therapy to be effective it must
translate well from rodents to humans and it must persist
over extended periods of time. To test both these parame-
ters a Rhesus macaque was infected with rAAV2-GFP at 100
days' gestation, allowed to deliver, and then tissues exam-
ined for GFP expression at 15 months of age (16 months
post-infection). This gestation time is comparable to that
used for both mice and rats (Figs. 1,2,3; [5]).BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/16
Page 3 of 8
(page number not for citation purposes)
rAAV2 mediated gene transfer in the mouse fetus Figure 1
rAAV2 mediated gene transfer in the mouse fetus. Fetuses at 15–16 day gestation were infected with rAAV2CMVgfp via intra-
amniotic transfer. At 72 hours post-infection whole fetuses were fixed and section for deconvoluting microscopic analysis. Sec-
tions were stained with the nuclear stain DAPI (blue) and phalloidin (red) staining of actin. A-lung; B-intestines; and C-kidney. 
Original magnification 630XBMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/16
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The lungs from the NHP showed both type I and type II
cells positive for GFP expression (Fig. 4, Panel A). These
cells were scattered throughout the lung parenchyma and
were readily apparent in all sections of the lung. Thus,
rAAV2 DNA and gene expression are maintained in lungs
of the NHP.
Like the lungs, the rhesus' intestines showed random
(<5%) villi positive for GFP (Fig. 4, Panel B). Because cells
in a villi turn over every 72 hours and differentiation
occurs outwardly from stem cells located in the crypt, this
distribution was consistent with the maintenance of indi-
vidual clones of stem cells transfected by the rAAV2. In
addition, the finding that only random villi were positive
for transgene expression was consistent with the rat stud-
ies where long-term gfp-specific DNA sequences could not
be detected. This suggests that only a small proportion of
stem cells in the intestine become infected with the trans-
gene and that maintenance of transgene expression over a
long period of time is reduced. In addition, the protein
appears to collect in the lacteal, which includes the lym-
phatics of the intestines.
The finding that transgene protein was present primarily
in the lacteal of the intestines suggests that either epithe-
lial cells were secreting the protein into the lymphatic
fluid or that phagocytic cells of the lymphatics were scav-
enging this protein. To determine if the transgene protein
was in phagocytic cells or free in the lymphatics, the sec-
tions were stained with both fluorescently labeled phal-
loidin toxins to stain membranes and DAPI for nuclei;
and they were then analyzed by high-resolution, deconvo-
luting microscopy. As shown in Fig. 5, GFP is not associ-
ated with specific cells but rather was present in the
lymphatic fluid of the intestines. Thus, the secretion of
transgene proteins from intestinal epithelial cells results
in release into the lymphatics. This finding would account
for the protein seen in the kidneys because the lymphatics
drain into the general circulation from which proteins
would be filtered by the kidneys.
Discussion
There are several features that make AAV2 an attractive
vector for gene therapy protocols. First, AAV2 has the abil-
ity to remain expressed throughout the full life cycle of a
cell by integrating into host cell DNA or remaining
episomal inside the cell. Wild-type adeno-associated virus
has been shown to integrate into chromosome 19 in the
host cell by non-homologous recombination mediated by
the rep gene products [9,10]. Recombinant AAV2 lacks the
rep gene has been shown to integrate nonspecifically into
host cell DNA or remain episomal. In either case, the
AAV2 genome is persistently expressed using the host
cell's machinery [11]. This feature is important in gene
therapy because it could allow for a single injection of a
therapeutic gene without the need for re-administrations.
It is well known that repeat administrations of a vector
GFP in rat lung at 9 months of age Figure 2
GFP in rat lung at 9 months of age. Lungs from rats infected 
in utero at 16 days gestation were fixed and mounted in paraf-
fin. GFP was visualized by immunohistochemistry staining. 
Original magnification 200X
GFP-specific sequences in rat lung at 12 months of age Figure 3
GFP-specific sequences in rat lung at 12 months of age. DNA 
was extracted from rat lungs. Undigested DNA (10 µg) was 
electrophoresed on agarose gel for Southern blot analysis. 
DNA from rAAV2gfp infected 293 cells was used as a posi-
tive control. Lanes labeled AAV-GFP represents DNA from 
separate animals infected at 16 days gestation with 
rAAV2gfp. Negative Control labeled lanes are from age-
matched animals not infected with an rAAV2.BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/16
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can lead to antibodies against the transgene, rendering it
ineffective.
Secondly, rAAV2 has broad transduction capabilities
because it is able to transduce many cell types including
the lungs, neurons, muscle, intestine and hematopoietic
cells [12]. In addition, rAAV2 can transduce mitotic and
post-mitotic cells [13]. At the time of injection, stem cells
in the lungs and intestines are undergoing rapid
differentiation and proliferation and therefore are easily
able to be transduced by rAAV2. Third, rAAV2 is an attrac-
tive vector because it is safe as compared to other viral vec-
tors. Ninety-six percent of the genome is removed when
preparing rAAV2 vectors because only the inverted termi-
nal repeats are needed for viral replication, packaging and
integration. In addition, for AAV2 to enter the lytic phase
of its life cycle it requires infection with a helper virus such
as adenovirus or herpes simplex virus. Otherwise, it
remains latent inside the host cell.
This paper demonstrates long-term transgene expression
following in utero transfer of rAAV2 into three species by
direct fluorescent visualization (Figs 1, 4, and 5), immu-
nohistochemistry (Fig. 2), and Southern blot analysis
(Fig. 3). There are several important considerations when
performing these in utero gene transfers. First, develop-
mental timing of therapy is perhaps the most significant
factor in successful gene transfer to the fetus. In all species
the cannalicular stage of lung development was targeted
in both rodents and non-human primates. This period
corresponds to 10–15 weeks' gestation in humans. The
dose of the virus is also a significant component of suc-
cessful intra-amniotic gene therapy. Excessive virus leads
to an immune response and loss of cells producing the
transgene. Finally, the anesthetic used can affect therapy.
Anesthesia is concentrated in the fetus and inhibits fetal
breathing and swallowing. Long-acting anesthetics such
as Ketamine interfere with transgene delivery. All animals
in this study, including NHPs, were anesthetized using
isoflurane only.
Recently, Boyle et al. [14] demonstrated gene transfer into
rabbit pulmonary epithelium using AAV2 with transgene
expression for only 24 days. This can be attributed to their
injection of the fetuses during the late saccular phase of
lung development. Recently, others have reported the use
Persistence and expression of transgenes following in utero rAAV2 gene therapy Figure 4
Persistence and expression of transgenes following in utero rAAV2 gene therapy. In utero gene therapy withrAAV2CMVgfp was 
performed in NHP and the tissues analyzed for GFP expression at 15 months of age. All sections were stained with the 
nuclear-specific DAPI (blue color) and visualized on a deconvoluting microscope. A – Lung; B – Intestines; and C – Kidney. 
Original magnification 630XBMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/16
Page 6 of 8
(page number not for citation purposes)
High resolution, three color analysis of GFP protein in NHP intestines Figure 5
High resolution, three color analysis of GFP protein in NHP intestines. Frozen sections from a 15 month old NHP were 
stained with the nuclear stain DAPI (blue color) and the actin-specific phalloidin conjugated to fluorescent marker (red color). 
Three dimensional reconstructions were performed on an automated, deconvoluting microscope. Original magnification 630XBMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/16
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of AAV2 for in utero gene therapy experiments and have
shown long-term expression of the transgene product in
target tissues for 3 months [15] to 18 months when given
intra-peritoneal [16].
Perhaps one of the more remarkable and important fea-
tures of in utero gene therapy presented in this paper is the
finding that with both adenoviruses [5] and rAAV2 (Figs.
1, 4, 5) the transgene product is continuously secreted
into the general circulation. The protein secretion is not
dependent upon the presence of a secretory signal as dem-
onstrated by both luciferase and beta-galactosidase (this
paper and [5]). As shown in the embryonic mouse, trans-
gene protein is secreted within 72 hours, and highly sig-
nificant quantities of the protein are readily apparent in
the kidney. The high resolution, 3-dimensional, deconvo-
luting microscopy analysis of NHP intestines at 15
months of age (16 months post-therapy) demonstrated
that epithelial cells of the intestines are secreting the trans-
gene protein into the lacteal for lymphatic drainage into
the general circulation via the thoracic duct. At the time of
in utero gene therapy, both the gut and lung are lined with
multipotential stem cells. Infection of these cells with
rAAV2 leads to a permanent population of cells producing
and secreting the transgene protein.
Conclusion
Given this data, in utero gene transfer with rAAV2 can be
useful in treating metabolic diseases by providing long-
term gene expression and significant circulating levels of
the transgene protein. Insertion of metabolic enzymes
active in plasma could alleviate certain genetic disorders.
Materials and methods
In utero gene transfer
Time-pregnant C57Bl/6 mice and Sprague-Dawley rats
(Harlan-Sprague-Dawley, Indianapolis, IN) were anesthe-
tized with isoflurane and the fetuses surgically exposed for
injection via amniotic fluid with replication defective
rAAV2 (rAAV2CMVgfp; generously provided by Dr. James
Wilson). The control fetuses were not injected. Time-preg-
nant Rhesus macaque was anesthetized only with isoflu-
rane; the fetus visualized by ultrasound; and the
recombinant virus delivered by trans-abdominal infection
into the amniotic fluid. All fetuses were treated with 108
pfu/ml of amniotic fluid.
Southern blot analysis
EGFP-plasmid DNA was subjected to PCR for amplifying
GFP to use as a probe in our Southern blot analysis. Using
the Qiagen Gel Extraction Kit Protocol, the GFP PCR frag-
ment was extracted and purified from the agarose gel.
Then using the Amersham Redi prime II system, the probe
was prepared by adding radiolabelled 32P-CTP to the puri-
fied GFP fragment. The agarose gel with uncut DNA from
each sample followed by transfer to nitrocellulose mem-
brane overnight using 2X SSC. Membranes were placed in
a hybridization tube with 15 mls of hybridization buffer
(Quik Hyb-Stratagene). The GFP probe was then added
and allowed to hybridize overnight. Finally the mem-
brane was exposed to film.
Histology
Aliquots of tissue were fixed in 4% paraformaldehyde
overnight for paraffin embedding. Tissues were parallel
processed with non-infected tissues. GFP expression was
confirmed by immunohistochemistry using a polyclonal
GFP antibody at a 1:1000 dilution. Control tissues
included uninfected tissues as well as tissues parallel proc-
essed without primary antibody. After antigen capture
(Vector Antigen Unmasking Solution), the tissue was
incubated at 4 degrees Celsius for 12 hours with primary
antibody and amplified with an avidin/biotin system
(Vectastain ABC Kit; Vector Laboratories, Inc., Burlin-
game, CA) and developed with 3-amino-9ethyl-carbazole
(Vector AEC Kit) and counterstained with hematoxylin.
Fluorescent imaging was performed on a deconvoluting
microscope. Nuclei were visualized by DAPI staining and
membranes by fluorescently labeled phalloidin. Fluores-
cent analyses of samples were performed in a Leitz decon-
voluting microscope. Untreated control and experimental
samples were digitally deconvolved (nearest neighbor
analysis) and color processed in parallel. Only when all
fluorescence in the wavelength with GFP was completely
eliminated from the control samples was documentation
of experimental samples performed.
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